| human | Q5 |
| P496 | ORCID iD | 0000-0002-9363-4103 |
| P735 | given name | Nicolette | Q19689352 |
| Nicolette | Q19689352 | ||
| P106 | occupation | researcher | Q1650915 |
| Q47940391 | 230th ENMC International Workshop:: Improving future assessment and research in IgM anti-MAG peripheral neuropathy: A consensus collaborative effort, Naarden, The Netherlands, 24-26 February 2017. |
| Q99731941 | A hereditary spastic paraplegia predominant phenotype caused by variants in the NEFL gene |
| Q39206609 | Anti-sulphatide antibodies in peripheral neuropathy |
| Q77292658 | Antiganglioside antibodies in polyneuropathy associated with monoclonal gammopathy |
| Q41638338 | Association of IgM monoclonal gammopathy with progressive muscular atrophy and multifocal motor neuropathy: a case-control study |
| Q53915734 | Benign prognosis in idiopathic hyper-CK-emia. |
| Q83980790 | CAV3 gene mutation analysis in patients with idiopathic hyper-CK-emia |
| Q39101583 | Changing outcome in inflammatory neuropathies: Rasch-comparative responsiveness |
| Q71828966 | Chronic idiopathic axonal polyneuropathy |
| Q77898662 | Chronic idiopathic axonal polyneuropathy and successful aging of the peripheral nervous system in elderly people |
| Q38210650 | Chronic idiopathic axonal polyneuropathy and vitamin B6: a controlled population-based study |
| Q36720383 | Chronic idiopathic axonal polyneuropathy is associated with the metabolic syndrome |
| Q49022231 | Chronic idiopathic axonal polyneuropathy. Comparison of patients with and without monoclonal gammopathy |
| Q33733455 | Chronic idiopathic axonal polyneuropathy: a five year follow up |
| Q33591880 | Chronic idiopathic polyneuropathy presenting in middle or old age: a clinical and electrophysiological study of 75 patients |
| Q47146553 | Chronic obstructive pulmonary disease is not a risk factor for polyneuropathy: A prospective controlled study |
| Q49089489 | Classical and lectin complement pathway activity in polyneuropathy associated with IgM monoclonal gammopathy |
| Q21202855 | Clinical features and predictors for disease natural progression in adults with Pompe disease: a nationwide prospective observational study |
| Q38208249 | Clinical phenotype of patients with neuropathy associated with monoclonal gammopathy: a comparative study and a review of the literature |
| Q90910196 | Clinical relevance of serum antibodies to GD1b in immune-mediated neuropathies |
| Q24628273 | Cold paresis in multifocal motor neuropathy |
| Q40798113 | Comparing the NIS vs. MRC and INCAT sensory scale through Rasch analyses |
| Q80418997 | Cytogenetic aberrations in neuropathy associated with IgM monoclonal gammopathy |
| Q43282864 | Detection of anti-MAG antibodies in polyneuropathy associated with IgM monoclonal gammopathy |
| Q73398521 | Development of weakness in patients with chronic inflammatory demyelinating polyneuropathy and only sensory symptoms at presentation: a long-term follow-up study |
| Q73254787 | Diagnostic criteria for demyelinating polyneuropathy associated with monoclonal gammopathy |
| Q73114376 | Diagnostic value of myotactic reflexes in axonal and demyelinating polyneuropathy |
| Q48402869 | Diagnostic value of sonography in treatment-naive chronic inflammatory neuropathies. |
| Q92577687 | Diagnostic value of symptoms in chronic polyneuropathy: The Erasmus Polyneuropathy Symptom Score |
| Q48691929 | Differences between hereditary motor and sensory neuropathy type 2 and chronic idiopathic axonal neuropathy. A clinical and electrophysiological study |
| Q53383981 | Disease course of Charcot-Marie-Tooth disease type 2: a 5-year follow-up study. |
| Q36319018 | Distribution of muscle weakness of central and peripheral origin. |
| Q24247228 | Drug therapy for chronic idiopathic axonal polyneuropathy |
| Q69336918 | Drug therapy for chronic idiopathic axonal polyneuropathy |
| Q36410068 | Drug therapy for chronic idiopathic axonal polyneuropathy. |
| Q36459627 | Effect of enzyme therapy and prognostic factors in 69 adults with Pompe disease: an open-label single-center study |
| Q36297853 | Effect of stem cell transplantation for B-cell malignancies on disease course of associated polyneuropathy |
| Q51755402 | Entrapment in anti myelin-associated glycoprotein neuropathy. |
| Q95416086 | Evidence-based guideline update: plasmapheresis in neurologic disorders |
| Q87215032 | Fcγ receptor IIIA genotype is associated with rituximab response in antimyelin-associated glycoprotein neuropathy |
| Q40089560 | Feasibility and cost efficiency of a diagnostic guideline for chronic polyneuropathy: a prospective implementation study |
| Q37478144 | Functioning of patients with chronic idiopathic axonal polyneuropathy (CIAP). |
| Q56008646 | Genetic heterogeneity in Miyoshi-type distal muscular dystrophy |
| Q38991068 | Grip strength comparison in immune-mediated neuropathies: Vigorimeter vs. Jamar |
| Q48024963 | High prevalence of the MYD88 L265P mutation in IgM anti-MAG paraprotein-associated peripheral neuropathy. |
| Q34189319 | Hyper-CK-aemia revisited |
| Q46801608 | Hypertension risk in idiopathic hyperCKemia |
| Q83115306 | Immunoglobulin gene analysis in polyneuropathy associated with IgM monoclonal gammopathy |
| Q24244144 | Immunosuppressive treatment for non-systemic vasculitic neuropathy |
| Q24246358 | Immunosuppressive treatment for non-systemic vasculitic neuropathy |
| Q38991147 | Impairment measures versus inflammatory RODS in GBS and CIDP: a responsiveness comparison |
| Q80863131 | In tandem analysis of CLCN1 and SCN4A greatly enhances mutation detection in families with non-dystrophic myotonia |
| Q41694795 | Incidence of polyneuropathy in Utrecht, the Netherlands |
| Q44578348 | Increase of sural nerve T cells in progressive axonal polyneuropathy and monoclonal gammopathy |
| Q73270564 | Indications for an immune-mediated etiology of idiopathic sensory neuronopathy |
| Q53980487 | Intermittent cyclophosphamide and prednisone treatment of polyneuropathy associated with monoclonal gammopathy of undetermined significance. |
| Q53185795 | Intermittent cyclophosphamide with prednisone versus placebo for polyneuropathy with IgM monoclonal gammopathy. |
| Q35467022 | Is cardiovascular disease a risk factor in the development of axonal polyneuropathy? |
| Q82377392 | Length dependence in polyneuropathy associated with IgM gammopathy |
| Q74527868 | MRI of the brachial plexus in polyneuropathy associated with monoclonal gammopathy |
| Q73343604 | Magnetic resonance imaging of the brachial plexus in patients with multifocal motor neuropathy |
| Q47584292 | Maintenance IV immunoglobulin treatment in chronic inflammatory demyelinating polyradiculoneuropathy |
| Q40505043 | Malignant transformation in polyneuropathy associated with monoclonal gammopathy |
| Q24562945 | Measuring ataxia: quantification based on the standard neurological examination |
| Q48587068 | Miyoshi-type distal muscular dystrophy. Clinical spectrum in 24 Dutch patients |
| Q49840773 | Nerve sonography to detect peripheral nerve involvement in vasculitis syndromes |
| Q79422696 | Neurologic and hematologic response to fludarabine treatment in IgM MGUS polyneuropathy |
| Q31845426 | Neuropathy and IgM M-proteins: prognostic value of antibodies to MAG, SGPG, and sulfatide |
| Q91584731 | Neuropathy associated with immunoglobulin M monoclonal gammopathy: A combined sonographic and nerve conduction study |
| Q84572560 | Pain in patients with chronic idiopathic axonal polyneuropathy |
| Q48418751 | Perceived control is a concurrent predictor of activity limitations in patients with chronic idiopathic axonal polyneuropathy |
| Q97589854 | Performance and self-reported functioning of people with Chronic Idiopathic Axonal Polyneuropathy (CIAP): a four year follow up study |
| Q33735180 | Peripheral Nerve Society Guideline on the classification, diagnosis, investigation, and immunosuppressive therapy of non-systemic vasculitic neuropathy: executive summary |
| Q76340267 | Peripheral nerve involvement in spinocerebellar ataxias |
| Q72406726 | Polyneuropathy associated with monoclonal gammopathy of undetermined significance. A prospective study of the prognostic value of clinical and laboratory abnormalities |
| Q45231930 | Prevalence, specificity and functionality of anti-ganglioside antibodies in neuropathy associated with IgM monoclonal gammopathy |
| Q59469513 | Prognosis of polyneuropathy due to IgM monoclonal gammopathy: A prospective cohort study |
| Q35688440 | Progressive idiopathic axonal neuropathy--a comparative clinical and histopathological study with vasculitic neuropathy |
| Q47577354 | Protocol of a dose response trial of IV immunoglobulin in chronic inflammatory demyelinating polyradiculoneuropathy (DRIP study). |
| Q73614193 | Pulsed high-dose dexamethasone treatment of polyneuropathy associated with monoclonal gammopathy |
| Q51081227 | Quality of life in patients with axonal polyneuropathy. |
| Q77886542 | Quantitative assessment of the innervation of epineurial arteries in the peripheral nerve by immunofluorescence: differences between controls and patients with peripheral arterial disease |
| Q84500145 | Randomised controlled trial comparing two different intravenous immunoglobulins in chronic inflammatory demyelinating polyradiculoneuropathy |
| Q98901054 | Randomised trial of intravenous immunoglobulin maintenance treatment regimens in chronic inflammatory demyelinating polradiculoneuropathy |
| Q50895036 | Rapid worsening of IgM anti-MAG demyelinating polyneuropathy during rituximab treatment. |
| Q38564562 | Recent advances in outcome measures in IgM-anti-MAG+ neuropathies |
| Q33968528 | Relationship between ischemia and neuropathy |
| Q44229084 | Response to exercise of patients with idiopathic hyper-CK-emia |
| Q53989179 | Response to intravenous immunoglobulin treatment in chronic inflammatory demyelinating polyneuropathy with only sensory symptoms. |
| Q74527859 | Risk factors for hematological malignancy in polyneuropathy associated with monoclonal gammopathy |
| Q43291179 | Rituximab for polyneuropathy with IgM monoclonal gammopathy |
| Q72712503 | Segmental fasciculations as a late sequel of spinal cord injury |
| Q86503267 | Serum IgG levels in IV immunoglobulin treated chronic inflammatory demyelinating polyneuropathy |
| Q92215974 | Serum cytokine patterns in immunoglobulin m monoclonal gammopathy-associated polyneuropathy |
| Q57200485 | Severe cardiac phenotype with right ventricular predominance in a large cohort of patients with a single missense mutation in the DES gene |
| Q36317109 | Sjögren's syndrome in patients with chronic idiopathic axonal polyneuropathy |
| Q84788927 | Small-fibre neuropathy can be detected in patients with chronic idiopathic axonal polyneuropathy |
| Q53316918 | Spinocerebellar ataxias in the Netherlands: prevalence and age at onset variance analysis. |
| Q91429247 | Statins do not increase risk of polyneuropathy: A case-control study and literature review |
| Q77543534 | Sural nerve T cells in demyelinating polyneuropathy associated with monoclonal gammopathy |
| Q72366403 | Temperature dependence of nerve conduction and EMG in neuropathy associated with gammopathy |
| Q84251802 | The additional yield of combined nerve/muscle biopsy in vasculitic neuropathy |
| Q39745143 | The epidemiology of neuromuscular disorders: Age at onset and gender in the Netherlands |
| Q33228491 | The meaning of distal sensory loss and absent ankle reflexes in relation to age: a meta-analysis |
| Q81814229 | The realistic yield of lower leg SNAP amplitudes and SRAR in the routine evaluation of chronic axonal polyneuropathies |
| Q48162386 | The role of nutrition as risk factor for polyneuropathy: a case-control study |
| Q42493266 | Thickness of endoneurial vessel basal lamina area in chronic idiopathic axonal polyneuropathy |
| Q73801593 | Three families with polyneuropathy associated with monoclonal gammopathy |
| Q24187168 | Treatment for IgG and IgA paraproteinaemic neuropathy |
| Q95290566 | Usefulness of a Double-Blind Placebo-Controlled Response Test to Demonstrate Rapid Onset Analgesia with Phenytoin 10% Cream in Polyneuropathy |
| Q40593249 | Validity of the shuttle walk test as a functional assessment of walking ability in individuals with polyneuropathy |
| Q24602603 | Wartenberg's migrant sensory neuritis: a prospective follow-up study |
| Q74474599 | [Clinical judgment and decision making in medical practice. A retiree with fatigue and foot drop] |
| Q72039907 | [Course of chronic idiopathic polyneuropathy during middle age and older: 2-year follow-up study] |
| Q74461189 | [Nerve circuit disorders: determination of polyneuropathy] |
| Q74461202 | [Referral of patients with polyneuropathy by the family physician: influence of type of symptoms but not of age] |
| Q77722094 | [The risk of Kahler disease (multiple myeloma) in patients with a paraproteinemia: myeloma risk score, developed in the region of the Integral Cancer Center, West] |
Search more.